Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9NRW3

UPID:
ABC3C_HUMAN

ALTERNATIVE NAMES:
APOBEC1-like; Phorbolin I

ALTERNATIVE UPACC:
Q9NRW3; B2R884; Q5JZ92; Q7Z2N7; Q96F12

BACKGROUND:
DNA dC->dU-editing enzyme APOBEC-3C, known alternatively as APOBEC1-like or Phorbolin I, is a critical inhibitor of retrovirus replication and retrotransposon mobility. It functions by converting cytosine to uracil in viral DNA, leading to significant mutations in the proviral genome. Its activity is selective for single-stranded DNA and does not affect double-stranded DNA or RNA. The enzyme's antiviral properties extend to viruses such as SIV, HBV, HHV-1, and EBV, and it may also influence the mobility of LTR and non-LTR retrotransposons.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of DNA dC->dU-editing enzyme APOBEC-3C offers a promising avenue for the development of novel therapeutic approaches, especially in the fight against viral diseases and in mechanisms of epigenetic gene regulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.